Disease relevance of SPINK7

• Short tandem repeat polymorphism in a novel esophageal cancer-related gene (ECRG2) implicates susceptibility to esophageal cancer in Chinese population [1].
• We have previously cloned and identified a novel esophageal cancer related gene 2 (ECRG2; GenBank Accession Number AF268198), which is down-regulated in esophageal squamous cell carcinoma (ESCC) and involved in the induction of the apoptosis in esophageal cancer cell lines [1].
• Adjusting for ECG 1 or ECG 2, autonomic scores, QTc interval, high density lipoprotein (HDL) cholesterol, 24 hour microalbuminuria, and 24 hour total proteinuria were significant [2].
• Overall, ECG1 was correctly identified as atrial fibrillation by 79% of physicians, ECG 2 was correctly identified as atrial fibrillation by 31%, and ECG 3 was correctly identified as atrial flutter by 90% [3].
• ECG 1 showed atrial fibrillation with prominent atrial activity (>0.2 mV) in lead V1; ECG 2 displayed atrial fibrillation with prominent atrial activity (>0.2 mV) in leads III and V1; and ECG 3 displayed atrial flutter [3].

High impact information on SPINK7

• Furthermore, comparison of the genotype distributions among other cancer sites might suggest that risk of the ECRG2 STR polymorphism might be specific to the esophagus [1].
• These findings indicate for the first time that the ECRG2 STR is a genetic susceptibility factor for ESCC and the TCA3/TCA3 allele might play a role in the development of this cancer [1].
• We performed a high-stringency scale procedure to screen ECRG2 against human fetal liver cDNA library and characterized positives by sequence analysis [4].

Biological context of SPINK7

• Esophageal cancer related gene2 (ECRG2) acts as a bi-functional gene associated with regulation of cell growth and death, and plays an important role in carcinogenesis of esophageal cancer [5].

Analytical, diagnostic and therapeutic context of SPINK7

• A total of 661 objects including 228 patients with ESCC and 373 normal controls were analyzed to investigate the impact of this ECRG2 STR polymorphism on risk of ESCC in case-control studies [1].
• In the present study, we have found a short tandem repeat (STR) polymorphism in the noncoding region of the exon 4 of the ECRG2 gene by using PCR-denaturing high-performance liquid chromatography (DHPLC) [1].
• The maximum ST elevation on ECG-1 was noted and > or = 30% ST resolution on ECG-2 was taken to represent partial/complete reperfusion [6].
• In ECG 2, complete (> or =70%) ST resolution was observed more often in the PTCA treated patients (35 vs 27%, P =.003) [7].
• Antibodies 8C9c53, 5E3c9, and 3C5c76, are suitable for detecting the ECRG2 on ELISA and Western blot assays, and 1E4c2 and 4B6c41 are suitable for immunofluorescence microscopy [5].

References